Roszkowski K, Nozdryn-Plotnicki B, Roszkowski W, Ko H L, Jeljaszewicz J, Pulverer G
J Cancer Res Clin Oncol. 1985;109(1):72-7. doi: 10.1007/BF01884258.
Seventy-nine patients with small-cell lung cancer were treated with vincristin, methotrexate, and cyclophosphamide in inductive therapy and with methotrexate, cyclophosphamide, and procarbazine in maintenance therapy. Patients were divided at random into two groups: one group received chemotherapy alone and the second group was additionally subjected to systemic immunotherapy with Propionibacterium granulosum strain KP-45. In general, differences in the frequency of therapy response and in duration of remission could not be stated between the two groups of patients, but patients responding to chemotherapy showed a significantly longer remission time and lower complication rates. This benificial effect of chemoimmunotherapy is not related to a direct antitumor activity of the immunomodifier used, but to the lowered risk of myelosuppression and infections. Immunomodulation in combination with chemo- and/or radiotherapy can be recommended for the treatment of small-cell lung cancer.
79例小细胞肺癌患者接受了诱导治疗，使用长春新碱、甲氨蝶呤和环磷酰胺，维持治疗使用甲氨蝶呤、环磷酰胺和丙卡巴肼。患者被随机分为两组：一组仅接受化疗，另一组额外接受颗粒丙酸杆菌菌株KP - 45的全身免疫治疗。总体而言，两组患者在治疗反应频率和缓解持续时间上没有差异，但对化疗有反应的患者缓解时间明显更长，并发症发生率更低。这种化疗免疫疗法的有益效果并非与所用免疫调节剂的直接抗肿瘤活性相关，而是与骨髓抑制和感染风险降低有关。免疫调节联合化疗和/或放疗可推荐用于小细胞肺癌的治疗。
